There are 2789 resources available
234P - Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
Presenter: Hope Rugo
Session: ePoster Display
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Presenter: Ye Guo
Session: ePoster Display
236P - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer
Presenter: Hope Rugo
Session: ePoster Display
Resources:
Abstract
Slides
274P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
Presenter: Thibault De La Motte Rouge
Session: ePoster Display
276P - Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial
Presenter: Min Yan
Session: ePoster Display
277P - Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B
Presenter: Hiroko Masuda
Session: ePoster Display
241P - Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2
Presenter: Jose Luis-Gonzalez Trujillo
Session: ePoster Display